124 related articles for article (PubMed ID: 37682707)
1. Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer.
Chiang CY; Fan S; Zheng H; Guo W; Zheng Z; Sun Y; Zhong C; Zeng J; Li S; Zhang M; Xiao T; Zheng D
Cell Rep; 2023 Sep; 42(9):113003. PubMed ID: 37682707
[TBL] [Abstract][Full Text] [Related]
2. SETD7 promotes metastasis of triple-negative breast cancer by YY1 lysine methylation.
Gao L; Zhang J; Long Q; Yang Y; Li Y; Li G; Pu P; Tong S; He Y; Li Q; Chen Y; Liu Y; Kong X
Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166780. PubMed ID: 37286143
[TBL] [Abstract][Full Text] [Related]
3. Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade.
Lv J; Wu Q; Li K; Bai K; Yu H; Zhuang J; Sun H; Yang H; Yang X; Lu Q
Int J Biol Sci; 2023; 19(12):3744-3761. PubMed ID: 37564199
[No Abstract] [Full Text] [Related]
4. Oncogenic KRAS effector USP13 promotes metastasis in non-small cell lung cancer through deubiquitinating β-catenin.
Guo Y; Tian J; Guo Y; Wang C; Chen C; Cai S; Yu W; Sun B; Yan J; Li Z; Fan J; Qi Q; Zhang D; Jin W; Hua Z; Chen G
Cell Rep; 2023 Dec; 42(12):113511. PubMed ID: 38043062
[TBL] [Abstract][Full Text] [Related]
5. [Research Progress of Role and Mechanism of SETD7 in Tumor Occurrence
and Progression].
Cao L; Wang M; Xu K
Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):38-45. PubMed ID: 36792079
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of SETD7 promotes migration and invasion of lung cancer cells via JAK2/STAT3 pathway.
Cao L; Ren Y; Guo X; Wang L; Zhang Q; Li X; Wu X; Meng Z; Xu K
Int J Mol Med; 2020 May; 45(5):1616-1626. PubMed ID: 32323737
[TBL] [Abstract][Full Text] [Related]
7. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
9. Isoform-Specific Lysine Methylation of RORα2 by SETD7 Is Required for Association of the TIP60 Coactivator Complex in Prostate Cancer Progression.
Song H; Chu JW; Park SC; Im H; Park IG; Kim H; Lee JM
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32120841
[TBL] [Abstract][Full Text] [Related]
10. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
11. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
Jiang L; Xu W; Chen Y; Zhang Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
[TBL] [Abstract][Full Text] [Related]
12. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between lysine methylation and phosphorylation of ATG16L1 dictates the apoptosis of hypoxia/reoxygenation-induced cardiomyocytes.
Song H; Feng X; Zhang M; Jin X; Xu X; Wang L; Ding X; Luo Y; Lin F; Wu Q; Liang G; Yu T; Liu Q; Zhang Z
Autophagy; 2018; 14(5):825-844. PubMed ID: 29634390
[TBL] [Abstract][Full Text] [Related]
14. CD44 promotes Kras-dependent lung adenocarcinoma.
Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
[TBL] [Abstract][Full Text] [Related]
15. Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study.
Ambrosini S; Montecucco F; Kolijn D; Pedicino D; Akhmedov A; Mohammed SA; Herwig M; Gorica E; Szabó PL; Weber L; Russo G; Vinci R; Matter CM; Liuzzo G; Brown PJ; Rossi FMV; Camici GG; Sciarretta S; Beltrami AP; Crea F; Podesser B; Lüscher TF; Kiss A; Ruschitzka F; Hamdani N; Costantino S; Paneni F
Cardiovasc Res; 2023 Jan; 118(17):3374-3385. PubMed ID: 35709329
[TBL] [Abstract][Full Text] [Related]
16. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
17. PKC
Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
[TBL] [Abstract][Full Text] [Related]
18. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
19. Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma.
Chen Y; Yang S; Hu J; Yu C; He M; Cai Z
PLoS One; 2016; 11(5):e0154939. PubMed ID: 27183310
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
